Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'
CNBC
Last updated: April 28, 2026
Novartis CEO Vas Narasimhan expressed significant concern regarding the U.S. drug pricing policy enacted under President Donald Trump. He anticipates that the current policy will create substantial difficulties for both pharmaceutical companies and patients in the near future.
- Novartis' CEO, Vas Narasimhan, voiced concerns on Tuesday about the U.S. drug pricing policy, describing it as a "very difficult situation." He believes the practical implications of these policies will soon become apparent to drug manufacturers and patients alike. The statement suggests that current pricing strategies are unsustainable in the long term. Narasimhan's remarks highlight a potential disconnect between policy intentions and market realities, implying that a tougher stance on drug prices could lead to unintended consequences. The focus is on the impending challenges and the need for adaptive strategies within the pharmaceutical sector to navigate these new regulatory pressures. This situation underscores the complex interplay between government policy, pharmaceutical innovation, and patient access to medication in the United States. The overarching sentiment is one of impending difficulty, signaling a period of adjustment for the industry.
